News ArchivesRead News
Medication Alone Insufficient in Treating Depression in Parkinson's Disease
Tuesday June 25, 2013
National Parkinson Foundation
Sacramento Bee - New findings from the National Parkinson Foundation (NPF) Parkinson's Outcomes Project show that antidepressants alone do not improve depression in Parkinson's disease. Depression was most effectively treated at centers that refer their depressed patients to a mental health professional or social worker. These findings were presented last week during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013.
In the study, "Approach to Treatment of Depression in Parkinson's Disease," Peter Schmidt, Ph.D., and colleagues examined which approaches to depression care correlated with the lowest prevalence of depression among patients seen at NPF's Centers of Excellence. Patients were treated with antidepressant medications, counseling by a social worker, treatment by a mental health professional, or a combination.
"This work is part of the larger NPF mission: to determine what works best in the treatment and care of Parkinson's with an aim toward slowing the impact of the disease," said Peter Schmidt, Ph.D., lead author of the study and Vice President, Programs at NPF. "This particular study highlights the importance of team care, something NPF has long advocated at its Centers of Excellence. We found the best care is achieved when neurologists coordinate with other health professionals to aggressively fight Parkinson's. In fact, a 'depression team,' consisting of a social worker and a psychiatrist coordinating with the neurologist, yielded the best results."
The study, analyzing 2,423 patients at 10 NPF Centers of Excellence found 1,121 depressed patients (46%), but at the best center only 30% showed signs of depression. Centers prescribed antidepressant medications to between 29% and 63% of their depressed patients, but high-prescribing centers achieved no significant reduction in depression versus low-prescribing centers. Other treatments, however, did correlate with better outcomes.
This work is part of the Parkinson's Outcomes Project, a longitudinal look at which treatments produce the best health outcomes. Started in 2009, the study represents data from more than 6,000 people with Parkinson's disease in four countries.
Recent NewsMay 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis
Apr 12 - Obstructive Sleep Apnea Affects Cognition in Parkinson's Disease
Apr 11 - Seattle boxing gym giving hope to Parkinson's patients
Apr 10 - A new rhythm
Apr 10 - Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapy
Apr 6 - FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
Apr 5 - Combatting the isolation of young onset Parkinson's disease
Apr 1 - The Kid is Alright